CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED China Traditional Chinese Medicine Holdings Co. Limited Stock
Equities
570
HK0000056256
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 HKD | -0.23% |
|
-0.46% | +9.67% |
| Sales 2023 | 18.12B 2.5B 19.61B | Sales 2024 * | 22.34B 3.09B 24.17B | Capitalization | 20.11B 2.78B 21.76B |
|---|---|---|---|---|---|
| Net income 2023 | 1.28B 178M 1.39B | Net income 2024 * | 1.36B 188M 1.47B | EV / Sales 2023 | 1.06 x |
| Net Debt 2023 | 1.24B 171M 1.34B | Net Debt 2024 * | 1.88B 260M 2.04B | EV / Sales 2024 * | 0.98 x |
| P/E ratio 2023 |
14
x | P/E ratio 2024 * |
14.9
x | Employees | 17,303 |
| Yield 2023 * |
1.88% | Yield 2024 * |
2.88% | Free-Float | 67.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.23% | ||
| Current month | +0.93% | ||
| 1 month | -0.46% | ||
| 3 months | +41.64% | ||
| 6 months | +26.69% | ||
| Current year | +9.92% |
1 week
4.30
4.36
1 month
4.274.36
Current year
2.804.38
1 year
2.804.68
3 years
2.626.74
5 years
2.626.74
10 years
2.627.57
| Managers | Title | Age | Since |
|---|---|---|---|
Li Xin Shen
DFI | Director of Finance/CFO | 58 | 21-09-02 |
Guoqiang Li
CTO | Chief Tech/Sci/R&D Officer | - | - |
Xue Ren Cheng
BRD | Director/Board Member | 60 | 18-12-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rong Xie
BRD | Director/Board Member | 71 | 13-02-04 |
Dong Ji Zhao
SEC | Corporate Secretary | 56 | 13-02-04 |
Tze Shan Yu
BRD | Director/Board Member | 67 | 13-11-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.50% | 2 M€ | -20.08% | - | |
| 0.06% | 11 M€ | -1.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 4.31 | -0.23% | 23 195 769 |
| 24-04-17 | 4.32 | 0.00% | 24,394,000 |
| 24-04-16 | 4.32 | 0.00% | 27,250,000 |
| 24-04-15 | 4.32 | -0.23% | 9,797,385 |
| 24-04-12 | 4.33 | 0.00% | 24,092,040 |
Delayed Quote Hong Kong S.E., April 18, 2024 at 02:24 am EDT
More quotes
China Traditional Chinese Medicine Holdings Co. Limited is principally engaged in the manufacture and sales of traditional Chinese medicine (TCM). The Company operates through 12 subsidiaries, including Sinopharm Group Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd., Sinopharm Group Luya (Shandong) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Medicinal Material & Slices Co., Ltd., Foshan Winteam Pharmaceutical Sales Company Limited, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Sinopharm Group Jingfang (Anhui) Pharmaceutical Co., Ltd., Sinopharm Group Longlife (Guizhou) Pharmaceutical Co., Ltd., Qinghai Pulante Pharmaceutical Co., Ltd., Guizhou Zhongtai Biological Technology Company Limited and its subsidiaries and Jiangyin Tianjiang Pharmaceutical Co., Ltd. and its subsidiaries.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.993
CNY
Average target price
4.342
CNY
Spread / Average Target
+8.73%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.92% | 2.78B | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- 570 Stock
